News and Announcements
Significant Advance in Development of Actinogen’s Alzheimer’s Drug
- Published December 19, 2016 1:09PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
19th December 2016 – ASX Announcement
- Xanamem™ human research data accepted for publication in major medical journal
- Xanamem™ specifically designed to inhibit excess cortisol production in the brain
- Excess cortisol in the brain associated with Alzheimer’s disease
- Xanamem™ being trialled in Alzheimer’s disease to confirm earlier treatment success
In significant advance in the development of Xanamem™, Actinogen Medical Ltd (ASX: ACW) in pleased to announce that their human research data on Xanamem™ has been accepted for publication in the prestigious pee-reviewed medical journal – the British Journal of Pharmacology. The paper: Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteriod dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™) will be available online early in the new year.
To view the full announcement please click on the button below.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
